What is Testosterone and why is it so important?

Leave a comment

Boston Testosterone Partners, Boston, Massachusetts

Testosterone is a hormone produced primarily in the male testes.  It is the lifeblood of every man.  Testosterone helps maintain men’s bone density, fat distribution, muscle strength and mass, red blood cell production, sex drive and sperm production.  It’s what makes men, men frankly.

The normal range for testosterone is wide, and men’s testosterone levels usually change throughout their lives.

Naturally, testosterone peaks during adolescence and early adulthood.  But as men get older, testosterone levels gradually fall – typically about 1 percent a year after age 30.   It is important to find out if low testosterone is a result of normal aging, or if it could be due to a medical problem.

Declines in testosterone levels can cause symptoms.  Fatigue and low sexual interest are the most common while some men also see changes in beard and body hair growth.  Muscle wasting and a decrease in muscle strength can be a result of low testosterone also.  ED can occur with testosterone deficiency.  Fat gains may also be a cause of your low testosterone levels.

Disorders that may lead to low testosterone include hypogonadism, rare conditions of the testicles or the pituitary gland in which the body does not produce sufficient or adequate amounts of testosterone.  Other conditions that can affect testosterone levels are environmental related, excessive weight gains, thyroid problems, obstructive sleep apnea, depression and excessive alcohol use.

Follow-up blood tests and examinations will show if a medical condition is contributing to low testosterone.  Blood testing will also show your free testosterone levels, or the amount that is bioavailable to us.  Proper blood testing will always include estradiol, a sister hormone of testosterone.  If an underlying medical condition is identified, treatment for that disorder may be all you need to bring your testosterone level back into the normal range.

Testosterone replacement therapy may be recommended to correct your testosterone deficiency.

If you feel that you may be suffering for any signs or symptoms of low testosterone, Contact Boston Testosterone Partners today for more information on how you can get tested.


Not feeling your old-self? Low Energy? Weight gain? Libido loss?

Been shrugged off by your primary care physician when you asked about your testosterone level?

Contact Boston Testosterone, the nation’s leading Men’s Health Clinic to get your hormones tested.

Don’t Delay – Get Tested!

“The Greatest Health of Your Life”℠
National Testosterone Restoration for Men
Wellness & Preventative Medicine
Boston Testosterone Partners/CORE New England

855-617-MEDS (6337)

Please LIKE our new BTP Superfoods Facebook Page:

Boston Testosterone Partners – New York Office Announcement

Leave a comment

Boston Testosterone Partners/CORE New England – The Leader’s in Men’s Health, Testosterone Therapies and Preventative Medicines

photo 1We are pleased to announce that former NY Jet Safety, Erik Coleman, has been named as the practice manager for our newest clinic, CORE New York.

In addition to all our Wellness and Preventative Medicines, Erik will also be conducting strength and conditioning coaching for our patients.

The new office is located in Woodbury, New York. 

In New York, please contact Erik to inquire about scheduling.

In New England (or outside of New York) please contact Charlie Blaisdell at CBlaisdell@CoreNewEngland.com or visit www.BostonTestosterone.com to learn about all the outstanding Men’s Health Therapies we offer!!

Erik Coleman
Practice Manager
150 Woodbury Ave.
Woodbury, NY 11979
Direct: 516-712-8231
Office: 516-283-2004




Boston Testosterone Partners Reviews

Leave a comment

The Testosterone Replacement Therapy here at Boston Testosterone Partners is renowned for our Reviews and Testimonials, as well as offering the low TRT costs.

Here’s one of our recent testimonial from our Boston Testosterone Facebook Testimonial Page:

My name is James Love and I want to thank Clinic Director Charlie Blaisdell and the entire medical staff at BTP for all bannerad-bostontestosteronepartners-02-160x600-Ver.02they have done to improve my quality of life. I highly recommend you contact them to get yourself tested.Let me explain, I’m a on call mechanic and I work a minimum of 12 hrs a day, I also have always tried to follow a workout routine to maintain my health and enjoy playing the strength sports. Over the last few years its become considerably more taxing on my body and it has become so easy to cut the most important aspects of my workouts out.As a result my body fat had gotten out of control and so had my blood pressure, and I just couldn’t make myself break the cycle. I kept watching TV and seeing Low T commercials so I read up on it and yes sir , that was me. I spoke to my doctor about testing my hormone levels but was informed he was opposed to testosterone treatments period. I was left out in the cold by him. That’s when a friend of mine referred me to the doctors of BTP. I joined the clinic and did everything as it was told to me by their doctors. The clinic director, Charlie Blaisdell, was there for whatever I needed and for every step of the way, from the doctors appointments, to the blood work reading and to helping me understand the meaning of the different therapies they offer.

I have now been with the group since mid January 2014 and I want you to know, I feel GREAT!! I married my fiancé we got a small gym in the garage and a room set up for cardio work, I now do my cardio at least 4 times a week as well as all my accessory work and reps, I started doing work with my church on my days off as well as some work within my community with some local kids. And a small home business to keep me busy on my off days and a little extra money. My blood pressure is now down as well as my body fat. Just knowing that I was taking this step forced me to reevaluate my diet so I eat lots of fresh vegetables and fruit with my BTP Superfood supplement.

I refer almost everyone I know to BTP. Honestly, if you are not feeling right anymore, you owe it to yourself to contact this group. I have noting but the highest praise for their skill, care and professionalism. I’m so enthusiastic about the way the BTP medical group has helped me that I am getting my wife in for therapy too.

One more thing, for a long time I felt I couldn’t afford this but I know now it’s not that expensive at all. And we should never put a price on our happiness and well-being.

Testosterone Replacement Therapy has gained in popularity among aging men.  Therapies offered at Boston Testosterone Partners improve sexual function, libido, energy, your overall sense of well being, lean muscle mass, fat decreases and strength. Testosterone Therapy has also been found to be beneficial in preventing heart disease, diabetes, and Alzheimers Disease.

Have you got your levels tested?  Primary Care Doctor shrugged you off when you asked?

Contact BTP to find out how you can get tested today! Read our testimonials posted to our Facebook Wall for more information on BTP and what our patients experience from optimized testosterone levels.

For more information and appointments, please contact Clinic Director Charlie Blaisdell at CBlaisdell@CoreNewEngland.com

BTP/CORE New England
920 Washington Street
Norwood, MA 02062
Clinic: 781-269-5953
Direct: 617-869-7961
Fax: 617-336-3400

Testosterone: The Lifeblood of Men

Leave a comment


Not feeling your old-self?  Low Energy?  Weight gain?  Libido loss?

Boston Testosterone Partners - The BEST Doctors in Testosterone Replacement Therapy

Boston Testosterone Partners – The BEST Doctors in Testosterone Replacement Therapy

Been shrugged off by your primary care physician when you asked about your testosterone level?  That all ends today..

Restore your original state of health and well-being with www.BostonTestosterone.com.

With over 38,000 Facebook Fans, find out why BTP/CORE is the nation’s top men’s health clinic, read our Patient Testimonials posted on our Testimonial Page –>http://goo.gl/l6cK9A.

No other Men’s Testosterone and Wellness Clinic in the nation has more personal and verifiable reviews than we do. No acronyms for names. Real men; real stories.

Call or write CORE New England’s Clinic Director, Charlie Blaisdell, for the best in Men’s Medical and Wellness Therapies.

BTP/CORE New England
920 Washington Street
Norwood, MA 02062
Clinic: 781-269-5953
Direct: 617-869-7961
Fax: 617-336-3400

Limited Time Promo Code: $50 off your signup —> https://www.formstack.com/forms/?1583926-2YMiYrW8R0

FDA Approves new Testosterone Replacement Therapy Injectables

Leave a comment

There’s only one way to do Testosterone Replacement Therapy, that’s with Injectable protocols.

Creams, gels and patches do not work well at all.

Contact us at www.BostonTestosterone.com for more information on our TRT protocols!

Read more about the new FDA Approved Testosterone Injectable:  http://goo.gl/DHnV3a


American Academy of Anti Aging

1 Comment

The below was issued on February 18, 2014 in response to the flawed TRT studies recently published.  Unfortunately the main stream media only seeks to fan the flames of any salacious stories rather than focus on the hundreds of studies that prove otherwise.  The media also ignores all the physicians, PhD’s and Harvard Medical School Professors who disagree with the failed study.

It is very important to note that these studies, while causally flawed, also found that there was no excess risk at all to men under 65 years old without a prior history of heart attacks.  

For more information call Boston Testosterone Partners at 855.617.6337 or visit our webpage at http://www.BostonTestosterone.com.


 A4M responds to Finkle W, et al “Increased risk of nonfatal myocardial infarction following testosterone therapy prescription in men” PLOS One 2014; DOI: 10.1371/journal.pone.0085805.

In response to William Finkle, et al. in PLOS One (29 Jan. 2014) the A4M finds the statistical study fails to represent an actual causal relationship between Testosterone therapy (TT) and myocardial infarction (MI).

Dr. Abraham Morgentaler, Associate Clinical Professor in the Department of Urology at Harvard University, writes the following regarding the statistical results of the study:  “It is possible that the men’s heart attacks in this study were caused by their underlying medical problems not testosterone…most heart attacks occurred in the first 90 days after a prescription was written.  It is unlikely that heart attacks could develop in such a short period of time.” (Featured interview:  USA Today Jan 29, 2014).

This statistical study is a manipulation of data, and does not represent an actual causal relationship between testosterone therapy and myocardial infarctions. These researchers’ statistical findings are extremely flawed as they don’t accurately account for any phenotypical variability or the fact that multi-factorial variables were not examined in their research project.  There was not any form of analysis of various serum parameters, ekg, exercise tolerance, muscle to fat ratio, the particular nature of testosterone therapy as well as dosing and administration of other drug interactions.  It is possible for any researcher to a manipulate a particular database and exhibit a correlational relationship between testosterone therapy and non-fatal myocardial infarctions.  It is also likely that the succinct population used in this study may have a greater disposition to cardiovascular events as compared to another cohort population of males over 65.

William Finkle et.  al. writes in their discussion that there are difficulties with this study.  The homogeneous database employed in this study is definitely not representative of other global heterogeneous databases, and most likely in terms of the correlational outcome of this study cannot be generalized to a larger population configuration.  This study should not have ever been published due to its methodological limitations, and Finkle et. al., did not review any of the other variables which needed to be analyzed in order to make an accurate assessment in terms of the relationship between exogenous testosterone normalization and cardiovascular morbidities.  The comparison that was employed in this study using the PDE5I group clearly makes this study invalid.  PDE5I induces vasodilation and therefore is not a valid control group.   What this study does point out is that actual research investigations should be conducted, in the rodent model as well as humans, about how higher levels of testosterone in the older phenotype impacts transcriptional and translation activities which eventuates in modifications in the cardiovascular system.  Furthermore, William Finkle et. al. did not consider any kind of epigenetic factors in his insufficient data analysis.  He is raising certain issues as to criteria which needs to be considered prior to a clinician prescribing testosterone for older males, such as certain phenotypes that should be excluded, based on their pathophysiology from receiving exogenous testosterone replacement.

Finkle et. al. states the following regarding the shortcomings of his study:  “Further study is needed to examine the risk of a variety of specific serious adverse cardiovascular events in relation to TT dose and duration, and to assess if the risks of TT vary by level of serum testosterone and presence or absence of hypogonadal disease”.  Paradoxically, these researchers discuss elsewhere “low endogenous testosterone levels may also be positively associated with cardiovascular events.”  This article makes salient many issues regarding this therapeutic protocol for the treatment of andropause in men.  Finkle  et.  al. does state that this therapy is pathophysiological, however, his correlational analysis as mentioned is flawed.  Clinicians should consider when prescribing testosterone to the older phenotype whether his overall health status or way of living should warrant this therapeutic protocol.
Finkle et. al.  did discuss some of the recognized side effects of testosterone therapy “increase of blood pressure, polycythemia, reduction in HDL cholesterol and hyper viscosity of blood and platelet aggregation.”  These pathophysiological parameters can be readily alleviated by a competent clinician with the employment of medicinal protocols.  It is not likely that polycythemia if regulated by a physician could engender cardiovascular events in the older phenotypes who have been placed on testosterone therapy. There have been a plethora of studies which have demonstrated that exogenous testosterone replacement to physiological levels does, in fact, mitigate the risk of cardiovascular morbidities.

Should a lethargic, obese, and hypertensive patient who is a borderline type 2 diabetic over 70 be prescribed exogenous testosterone therapy?  The physiological parameters of a male patient that is highly educated and involved in cardiovascular exercise programs, and who has an optimal fat to muscle ratio with an exquisite BMI is very different from an obese, hypertensive, pathogenic 65 year old male phenotype.  There is certainly more risk associated with the prophylaxis of a pathophysiological male compared to those optimally conditioned older cohorts.  In the hands of a highly qualified Anti-Aging physician, practicing preventative endocrinological therapies aka Anti-Aging Medicine (see http://www.worldheath.net),  testosterone replacement therapy can be used in conjunction with exercise, dietary manipulation and other cardiovascular risk factor reductions including the routine monitoring of hematocrit, blood viscosity, platelet counts and other indicators of polycythemia.  It is also common practice to remove 100-200cc of whole blood in individuals who are on long-term testosterone therapy to maintain optimal indices.

This article has caused unwarranted and exaggerated fears in the media and in the non-medically trained public. It has already induced unwanted trepidation regarding this medicinal therapy which has for the preceding 50 years improved the quality of life in millions of males and females.  The popular media will interpret the results of this skewed correlational study, which is unrepresentative of the overall older male population, as causing myocardial infarctions in patients being titrated with this therapeutic strategy.  However, physicians have the responsibility to judiciously manage patients in older phenotypes with multiple co morbidities.

At the most recent ENDO 2013 Annual Meeting (sponsored by The Endocrine Society), many of the speakers from the international endocrinology community lauded Testosterone therapy as an extremely viable prophylaxis for the mitigation of the symptomology associated with aging-related declines in male hormones.  There was no discussion of increased risk of cardiovascular morbidity with properly administered and monitored Testosterone therapy.  The speakers at the Winter 2013 Session of the 22nd Annual Congress on Anti-Aging Medicine, sponsored by the American Academy of Anti-Aging Medicine (A4M; http://www.worldhealth.net & http://www.a4m.com), held December 2013, also lectured on this topic.  These speakers cited overwhelming evidence of benefits of Testosterone therapy; and this protocol for the treatment of Testosterone decline reduced the risk of myocardial infarction.

Submitted by:
Ron Shane, PhD., O.M.D.
Tina Miranda, M.D., M.B.A., Diplomate ABIM
Karan Pandar
Ronald Klatz, M.D., D.O., President, A4M
Sharon McQuillan, M.D.
Jeffry S. Life, M.D. Ph.D.

Can Testosterone Cypionate Injections be done subcutaneously (sub-Q)? – Boston Testosterone Partners

Leave a comment

The question gets asked by many men when they begin testosterone therapy with BTP.  The answer is yes!   The risk is always in forming an abscess, but in our experience, using .5 mls of less per sub-Q shot leaves very little risk of that.

While intramuscular injections are the preferred manner of administration, sub-Q shots are gaining popularity among men across the country who restore their testosterone.

Contact Boston Testosterone Partners for more information on our Testosterone Replacement Therapies and Preventative Medicines.



Saudi Med J. 2006 Dec;27(12):1843-6.

Subcutaneous administration of testosterone. A pilot study report.

Al-Futaisi AMAl-Zakwani ISAlmahrezi AMMorris D.
Department of Medicine, College of Medicine & Health Sciences, Sultan Qaboos University, Muscat, Oman. alfutaisi@squ.edu.om


OBJECTIVE: To investigate the effect of low doses of subcutaneous testosterone in hypogonadal men since the intramuscular route, which is the most widely used form of testosterone replacement therapy, is inconvenient to many patients.

METHODS: All men with primary and secondary hypogonadism attending the reproductive endocrine clinic at Royal Victoria Hospital, Monteral, Quebec, Canada, were invited to participate in the study. Subjects were enrolled from January 2002 till December 2002. Patients were asked to self-administer weekly low doses of testosterone enanthate using 0.5 ml insulin syringe.

RESULTS: A total of 22 patients were enrolled in the study. The mean trough was 14.48 +/- 3.14 nmol/L and peak total testosterone was 21.65 +/- 7.32 nmol/L. For the free testosterone the average trough was 59.94 +/- 20.60 pmol/L and the peak was 85.17 +/- 32.88 pmol/L. All of the patients delivered testosterone with ease and no local reactions were reported.

CONCLUSION: Therapy with weekly subcutaneous testosterone produced serum levels that were within the normal range in 100% of patients for both peak and trough levels. This is the first report, which demonstrated the efficacy of delivering weekly testosterone using this cheap, safe, and less painful subcutaneous route.

PMID: 17143361 [PubMed – indexed for MEDLINE]




M.B. Greenspan, C.M. Chang
Division of Urology, Department of Surgery, McMaster University,
Hamilton, ON, Canada

Objectives: The preferred technique of androgen replacement has been intramuscular (IM) testosterone, but wide variations in testosterone levels are often seen. Subcutaneous (SC) testosterone injection is a novel approach; however, its physiological effects are unclear. We therefore investigated the sustainability of stable testosterone levels using SC therapy. Patients and methods: Between May and September 2005, we conducted a small pilot study involving 10 male patients with symptomatic late-onset hypogonadism.

Every patient had been stable on TE 200 mg IM for 1 year. Patients were instructed to self-inject with testosterone enanthate (TE) 100 mg SC (DELATESTRYL 200 mg/cc, Theramed Corp, Canada) into the anterior abdomen once weekly. Some patients were down-titrated to 50 mg based on their total testosterone (T) at 4 weeks.

Informed consent was obtained as SC testosterone administration is not officially approved by Health Canada. T levels were measured before and 24 hours after injection during weeks 1, 2, 3, and 4, and 96 hours after injection in week 6 and 8. 

At week 12, PSA, CBC, and T levels were measured however; the week 12 data are still being collected. 

Results: Prior to initiation of SC therapy, T was 19.14+3.48 nmol/l, hemoglobin 15.8+1.3 g/dl, hematocrit 0.47+0.02, and PSA 1.05+0.65 ng/ml. During the first 4 weeks, there was a steady increase in pre-injection T from 19.14+3.48 to 23.89+9.15 nmol/l (p¼0.1). However, after 8 weeks the post-injection T (25.77+7.67 nmol/l) remained similar to that of week 1 (27.46+12.91 nmol/l). Patients tolerated this therapy with no adverse effects. 

Conclusions: A once-week SC injection of 50-100 mg of TE appears to achieve sustainable and stable levels of physiological T. This technique offers fewer physician visits and the use of smaller quantity of medication, thus lower costs. However, the long term clinical and physiological effects of this therapy need further evaluation.

Older Entries